.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
This systematic review and meta-analysis pooled 12 randomized controlled trials (2,429 patients; 1,202 MMAE, 1,227 control), including the 2026 EMMA-Can, G-MEMBRANE and MEMBRANE trials, to evaluate middle meningeal artery embolization (MMAE) for chronic subdural hematoma. Study-defined treatment failure occurred in 9.1% of patients with MMAE versus 18.3% with standard management (RR 0.52, 95% CI 0.39–0.69), corresponding to an absolute risk reduction of 8.8% and a number needed to treat of about 12. Reoperation or surgical rescue was also lower (4.4% vs 11.6%; RR 0.40, 95% CI 0.31–0.52). The benefit was consistent across surgery-only and mixed comparator subgroups (P for subgroup difference=0.317). All-cause mortality (RR 0.72, 95% CI 0.37–1.43) and severe adverse events (RR 0.83, 95% CI 0.60–1.16) did not differ significantly. Certainty of evidence was moderate for efficacy outcomes and low for mortality and safety outcomes.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
This systematic review and meta-analysis pooled 12 randomized controlled trials (2,429 patients; 1,202 MMAE, 1,227 control), including the 2026 EMMA-Can, G-MEMBRANE and MEMBRANE trials, to evaluate middle meningeal artery embolization (MMAE) for chronic subdural hematoma. Study-defined treatment failure occurred in 9.1% of patients with MMAE versus 18.3% with standard management (RR 0.52, 95% CI 0.39–0.69), corresponding to an absolute risk reduction of 8.8% and a number needed to treat of about 12. Reoperation or surgical rescue was also lower (4.4% vs 11.6%; RR 0.40, 95% CI 0.31–0.52). The benefit was consistent across surgery-only and mixed comparator subgroups (P for subgroup difference=0.317). All-cause mortality (RR 0.72, 95% CI 0.37–1.43) and severe adverse events (RR 0.83, 95% CI 0.60–1.16) did not differ significantly. Certainty of evidence was moderate for efficacy outcomes and low for mortality and safety outcomes.
Today
Researchers have identified compound 8g, an orally bioavailable corydamine derivative that targets glutathione reductase. By dismantling redox defenses and disrupting NADPH homeostasis, 8g acts synergistically with sorafenib to trigger apoptosis and overcome drug resistance in hepatocellular carcinoma models.
Today
Ascertainment bias in cancer case-control studies inflates odds ratios and penetrance estimates when cases are drawn from high-risk clinics. A landmark modeling study demonstrates substantial bias ranging up to 23.72, highlighting the critical need for ascertainment adjustment in genetic risk counseling.
Today
Researchers demonstrate that central induction of synthetic torpor in non-hibernating rats provides striking cardioprotection, reducing myocardial infarct size by ~40% during ischaemia-reperfusion injury through endogenous survival signaling, independent of hypothermia.
Today
Chronic nonbacterial osteomyelitis (CNO) is a pediatric autoinflammatory bone disorder. This review covers the French protocol, emphasizing whole-body MRI as the diagnostic gold standard, prudent biopsy avoidance, first-line NSAID treatment, and second-line biologic or bisphosphonate therapies for spinal lesions.
Today
A novel fluorine-functionalized near-infrared copper fluorescent probe selectively illuminates lung tissue, revealing critical links between hyperglycemia, ER stress, and pulmonary malignancy for improved early diagnosis.
Today
